ICU antibiotics under scrutiny: new study targets hidden brain risks
NCT ID NCT03628300
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 400 intensive care patients receiving beta-lactam antibiotics to see how often these drugs cause brain-related side effects like confusion or agitation. Researchers measured antibiotic levels in the blood and checked patients' neurological status several times a week. The goal is to better understand and prevent these side effects in critically ill patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- beta-lactam antibiotics
- What this could lead to
- If successful, this could lead to safer dosing guidelines for beta-lactam antibiotics in intensive care, reducing the risk of brain-related side effects.
- What could go wrong
- This is an observational study, not a treatment trial. It may not produce clear-cut recommendations, and results may not apply to all ICU patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
400 people
The number who actually took part.
- Started
-
Jan 2017
- Finished
-
Jul 2017
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This is a prospective cohort study evaluating change in neurological status of patients admitted to the ICU and treated with a beta-lactam antibiotic with therapeutic drug monitoring. Neurological evaluation and scoring (Glasgow scale, CAM-ICU, Richmond agitation-sedation scale) and beta-lactam serum concentration assay are performed together 2 to 3 times a week.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients admitted to the ICU * Treatment initiation by an antibiotic of the beta-lactam class * Beta-lactam therapeutic drug monitoring Exclusion criteria: * Any neurological disorder already present at admission * Patients on mechanical ventilation who presented a neurological disorder before being intubated and sedated
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens-Picardie
Amiens, 80054, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Common Anti-Nausea drugs under scrutiny for kidney risk during chemo
- Heart attack delay may signal kidney risk after angioplasty
- What makes a hospital Low-Resource? global panel seeks a common answer
- ICU kidney injury: does the pattern predict lasting damage?
- Can two blood markers catch sepsis before it turns deadly?
- Can a kidney ultrasound scan warn of kidney damage after heart bypass surgery?